People with neurogenic overactive bladder from either multiple sclerosis or spinal cord injury often suffer significant morbidity and decreased quality of life. Here we review the pathophysiology of neurogenic overactive bladder and the impact it can have on people with multiple sclerosis or spinal cord injury. We also address the various traditional treatment options and focus on the use of botulinum toxin A (specifically onabotulinumtoxinA) for this condition.
Introduction
Overactive neurogenic bladder is a common problem in people who have multiple sclerosis (MS) and in those with spinal cord injury (SCI). Treatment for neurogenic overactive bladder has improved in recent decades with corresponding reductions in mortality. However, morbidity from neurogenic overactive bladder remains a primary issue for these two patient populations. For example, problems with incontinence may lead to social and vocational isolation, recurrent infections with associated antibiotic resistance, hydronephrosis, renal failure, and other associated issues.
Up to 96% of individuals with MS report issues with their bladder, 1 with 41% reporting significant frequency and 39% reporting urge incontinence. Urinary problems impact emotional health (31%), ability to perform household chores (22%), and physical recreation (28%), suggesting substantial disability. Bladder issues also have a significant impact on health in people with SCI. As a result, improving bladder function is a top priority among people living with SCI. [2] [3] [4] In this review, we define neurogenic overactive bladder and discuss the impact this condition has in the MS and SCI populations. We also provide a comprehensive review of the pathophysiology in order to understand the goals of therapy and the treatments available, with a special focus on evidence for the use of onabotulinumtoxinA.
Definitions
The International Continence Society (ICS) 5 defines the symptom syndrome of overactive bladder as "symptoms of urgency, with or without urge incontinence, usually with frequency and nocturia". Overactive bladder can be further defined as having neurologic causes or being idiopathic when there is no clear cause. However, the definition given by the ICS is not always applicable to people with SCI or MS, because it implies that the person with overactive bladder has sensations of urgency. In reality, many people with these neurologic conditions do not have any sensation in their bladder, of urgency or other. Thus, overactive bladder can be better refined as failure to relax during filling and/or involuntary or reflex contractions of the bladder during filling affecting the deferment of micturition until appropriate. Some refer to the difficulties people have with neurogenic overactive bladder as neurogenic detrusor overactivity; according to the ICS, the term "detrusor overactivity" specifically refers to a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. The ICS further categorizes detrusor overactivity as neurogenic detrusor overactivity (NDO) or idiopathic detrusor overactivity.
Pathophysiology
Characteristic of central nervous system lesions, the pathological changes associated with SCI and MS typically cause upper motor neuron syndrome. The disruption or lack of descending inhibitory fibers from the brain to the spinal cord leave reflex centers within the spinal cord unchecked, causing spasticity, increased/pathologic reflexes and clonus, as well as weakness. Just as a stretch of a skeletal muscle in the limb of a person with upper motor neuron syndrome may result in an overactive reflex firing without the descending inhibition, stretch of the bladder caused by urinary filling similarly can lead to uninhibited contractions of the detrusor, even at small volumes.
Despite classical teaching that the overactive reflexes in the detrusor are solely due to lack of descending inhibition from the cerebrum and pons, the other contributing factor in people with MS or SCI appears to be the predominance of activity in C-fibers as the primary afferent component of the reflex arc, compared with the usual predominance of A-delta fibers in the non-neurogenic bladder. These C-fibers are relatively "silent" in the non-neurogenic population, and "wake up" or increase in responsiveness after injury to the spinal cord, responding to distension of the bladder with small volumes and causing early stimulation of the reflex arc, which then fires out of control without descending inhibition from the cortex and brainstem. This concept of post-injury shift to a predominance of C-fibers after SCI was first found in spinalized cats, 6, 7 but later confirmed in humans by the observation of significant hyperresponsiveness to intravesical capsaicin (a C-fiber neurotoxin) in people with SCI or MS. 8, 9 Plastic changes with overexpression of other afferent receptors in the suburothelium, such as transient receptor potential cation channel subfamily V member 1 and P2X3 purinoreceptor 10 and neuropeptides such as substance P and calcitonin gene-related peptide after a spinal cord lesion have also been documented. With overexpression of these afferent receptors and increased stimulation of afferents by neuropeptides, the reflex arcs of the bladder are overstimulated and thus have a strong role in the pathophysiology of NDO 11 (see Figure 1 ).
In addition to an overactive detrusor leading to difficulties with storage and incontinence, many people with SCI or MS also have reflex overactive contractions of the external and/or internal sphincter(s), leading to difficulty with complete or total emptying. This is due to a disconnect between the sacral voiding center, spinal sympathetic outflow, and the voiding coordination center in the pons (specifically with suprasacral/infrapontine lesions). This combination of an overactive detrusor causing strong, overactive, and involuntary contractions, in addition to the outlet not relaxing appropriately, is known as detrusor sphincter dyssynergia (DSD). Although some people with MS or SCI have more synergistic overactive voiding and others have an areflexic bladder (eg, those with cauda equina syndrome), DSD is by far the most common presentation of neurogenic bladder in people with MS or SCI. As such, DSD is the primary focus of this paper.
Clinical sequelae of neurogenic overactive bladder with DSD
Such incoordination of the overactive detrusor and sphincter results in:
• inability to completely empty the bladder when the detrusor does contract because the outlet is also closed, causing urinary stasis and overdistension of the bladder • high pressures in the bladder due to firing against a closed outlet, resulting in increased ureteric pressures and possibly vesicoureteral reflux, leading to increased risk of hydronephrosis, pyelonephritis, and renal damage • incontinence, leading to embarrassment, social and vocational isolation, and skin irritation/breakdown • autonomic dysreflexia (typically for people with SCI lesions at T5 or higher), increased spasticity, and increased neurogenic pain. 
Prognosis of kidney function with DSD
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OnabotulinumtoxinA in SCi and MS patient requests stop of filling), which tends to be small in this population, reflex detrusor volume (when an involuntary contraction first occurs), and maximum detrusor pressure. The detrusor pressure is calculated by subtracting the pressures taken from a catheter in the rectum (abdominal pressure) from the pressures measured from a catheter inside the bladder (intravesical pressure). This subtraction of the abdominal pressure allows for pressures coming from cough and Valsalva maneuvers to be eliminated. Measuring the detrusor pressure is particularly important, given that the risk of upper tract deterioration increases when the detrusor leak point pressure consistently exceeds 40 cm H 2 O. 12 Sustained pressures of .40 cm H 2 O can eventually result in decreased transport of urine from the kidney, possible ureteric and renal reflux, and direct transmission of the detrusor pressure to the papillae in the kidney. This can lead to renal damage and failure in these patients, and hence the importance of maintaining lower bladder pressures.
Treatment goals and therapeutic options
The goals of treatment for neurogenic overactive bladder with DSD are to obtain low-pressure filling, have regular and complete emptying, improve bladder capacity, and avoid incontinence.
Clean intermittent catheterization (CIC) was first described in 1972 as a means of emptying the bladder in those with either upper or lower motor neuron lesions causing bladder dysfunction. 13 CIC is now the gold standard for long-term management in people with SCI or MS who cannot otherwise empty the bladder adequately. The goal is for the patient to catheterize every 4-6 hours or frequently enough to keep volumes less than 500 cc, and to avoid incontinence in between times. If patients are performing CIC but having incontinence in between times, or have evidence of high pressures despite CIC, then medications as described below should be initiated. These medications may also be used in people who still void, but are symptomatic with overactive bladder. Typical therapy for decreasing detrusor contractions in order to avoid elevated filling pressures is anticholinergic medication. This class of medication primarily targets the muscarinic receptors in the detrusor wall. The most commonly used traditional medication in this class is oxybutynin. However, due to the nonselective nature of blocking muscarinic receptors elsewhere throughout the body, oxybutynin and other traditional anticholinergic medications are associated with many unwanted side effects, including dry mucous membranes, constipation, cognitive dysfunction (due to the ability to cross the blood-brain barrier), worsening of temperature regulation, cardiac arrhythmias, accelerating severity of narrow-angle glaucoma (thus contraindicated in this condition), and others. Given the high incidence of concomitant brain injury in people with traumatic SCI and the high incidence of cognitive impairment in people with MS, the effect of crossing the blood-brain barrier, and thus blocking brain muscarinic receptors, is of particular concern in these two populations. Similarly, people with SCI or MS also typically have a neurogenic bowel, and exacerbation of their symptoms via anticholinergic side effects is often problematic. People with SCI are known to have autonomic dysfunction, making temperature regulation a particular issue that is often exacerbated by medication with anticholinergic properties.
Newer anticholinergic medications are more specific blockers of muscarinic-3 subtype acetylcholine receptors and can help to diminish the numerous side effects of traditional anticholinergics, 14 such as less drying of the mucous membranes, 15 and lower the risk of cardiac dysfunction. Furthermore, medications with a larger molecular size are less likely to cross the blood-brain barrier, thereby reducing the risk of cognitive dysfunction. 16, 17 Sustained-release anticholinergic medication options (longacting oral or transdermal patch formulations) can also decrease the side effects typically associated with rapidrelease formulations, because plasma blood levels can be maintained more consistently without the variability found with oral, regularly acting oxybutynin formulations.
A new class of medications, ie, agonists of the β3 receptors in the detrusor, are promising for people with MS or SCI. Stimulation of β3 receptors enables relaxation of the detrusor during filling, yet appears to cause minimal dryness of the mouth. 18 Unfortunately, there are no published studies to date of the efficacy of this class of medication in neurogenic overactive bladder.
Despite the advances made in the management of neurogenic bladder care in the last 40 years as described above, many people with MS or SCI have ongoing issues with overactive bladder (incontinence, frequency, urgency, and high detrusor pressures causing reflux, hydronephrosis, and renal failure). Many are intolerant of anticholinergic medications for the reasons discussed above, or continue to have issues of overactive bladder despite high doses of these agents. In the past, the only option was to insert an indwelling catheter, do a sphincterotomy and wear a condom for drainage (in men), or to have bladder augmentation surgery or urinary diversion.
Botulinum toxin A for neurogenic overactive bladder
The first application of botulinum toxin A for bladder dysfunction was described in the 1980s, with injections of onabotulinumtoxinA into the external urethral sphincter in order to decrease outlet resistance and treat DSD. 19 This was further explored in a recent meta-analysis of the small number of studies available, totaling 129 subjects, which indicated that this therapy can significantly decrease postvoid residuals at 1 month from 251.8 mL to 153.0 mL, and decrease detrusor pressures from 88.7 cm H 2 O to 20.5 cm H 2 O. 20 As such, treatment to the detrusor wall itself with onabotulinumtoxinA via cystoscopic needle injections into 20-30 sites throughout the detrusor has emerged as the most useful and efficacious treatment for those intolerant of or not responding to anticholinergic medication.
Intradetrusor onabotulinumtoxinA treatment was first described in an open-label, uncontrolled trial in 2000 by Schurch et al, 21 with a larger open-label description of 200 patients by Reitz et al in 2004. 22 The first multicenter, randomized, placebo-controlled trial of detrusor injections of onabotulinumtoxinA, published by Schurch et al in 2005, found significant improvements in the onabotulinum-toxinA group, and this effect continued at the study exit of 6 months. 23 Herschorn et al reported similar efficacy in a placebo-controlled trial, but extended the trial to show an effect lasting for at least 36 weeks from one injection. 24 Since that time, there have been a number of randomized, placebo-controlled trials confirming the efficacy of onabotulinumtoxinA in the treatment of neurogenic overactive bladder in people with MS or SCI. In particular, 
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OnabotulinumtoxinA in SCi and MS two large, multicenter, randomized, double-blind, 52-week Phase III studies, 25, 26 performed in people with MS or SCI receiving either 200 U or 300 U of onabotulinumtoxinA, reported dramatic results in both groups when compared with placebo for the primary outcome measure of decreased urinary incontinence at 6 weeks (P,0.001). The combined results also showed a decrease in urinary incontinence episodes by .20 per week. 27 Results for all secondary outcomes were also significant, and included decreased detrusor pressures at first reflex contraction (+1. 1 28 also improved (P,0.001). Duration of effect was based on when subjects asked for retreatment, and was 25.3 weeks in the 200 U group, 24.8 weeks in the 300 U group, and only 13.1 weeks in the placebo group; however, subjects were not allowed to request retreatment before 12 weeks. The most important clinical side effect was the need for de novo catheterization due to new urinary retention and high post-void residuals in the group that could void at baseline (the nonintermittent catheterization group). The need for de novo catheterizations was 7% in the placebo group, 31% in the 200 U group, and 44% in the 300 U group. However, interestingly, the need for de novo catheterizations in these groups did not affect quality of life, ie, these subjects had significant improvement in quality of life scores similar to those who did not have de novo intermittent catheterizations.
Botulinum toxin B (rimabotulinumtoxinB) has also been used for treatment of refractory detrusor overactivity with good efficacy, but seems to have a shorter therapeutic effect than onabotulinumtoxinA, and has been associated with more autonomic side effects. 29
Mechanism of action
It is well known that botulinum toxin A works on the efferent peripheral nervous system by blocking release of acetylcholine from presynaptic nerve endings into the neuromuscular junction, leading to a decrease in muscular contraction. However, more recent evidence suggests an additional mechanism in suppressing neurogenic bladder overactivity, with onabotulinumtoxinA targeting the afferent system as well. Apostolidis et al discovered that onabotulinumtoxinA has an inhibitory influence on neurotransmitters and receptors mediating sensory neurotransmission in the bladder wall, specifically the P2X3 and transient receptor potential cation channel subfamily V member 1 sensory receptors. 30 In mouse models, the increased sensitivity of afferent nerves to mechanical stimulation after spinal cord transection was reduced by onabotulinumtoxinA. 31 
Dosing and pattern of injections Dosing
Doses of onabotulinumtoxinA used in the trials for NDO have varied, usually being 200 U or 300 U, with 10 cc dilution per 100 U vial (1 cc per 10 U) and a 1 cc volume injected into 20-30 sites. In the two recent Phase III studies discussed above, 25, 26 there were significant improvements using the 200 U and 300 U doses compared with placebo, but no significant dose-related improvements when comparing the 200 U and 300 U doses. However, the side effects of urinary retention and need for intermittent catheterization de novo among those voiding at baseline were more common in those who received 300 U (44%) than in those who received 200 U (31%). 25, 26 Due to the similarly dramatic efficacy of the 200 U and 300 U doses, but the higher number of adverse events in the 300 U group, regulatory bodies in the USA, Canada, and Europe have approved intradetrusor administration of onabotulinumtoxinA 200 U for treatment of NDO. Some pilot work 32 investigating the use of a low dose (100 U) of onabotulinumtoxinA in 12 patients with MS and NDO who were still voiding reported that maximum bladder capacity significantly increased, maximum detrusor pressure decreased, and daytime and nighttime frequency, urgency, and pad use significantly decreased. Post-void residual volume increased significantly from an average of 98 cc at baseline to an average of 222 cc at 6 weeks, but decreased to an average of 135 cc by 12 weeks. The average time to reinjection was 8 months. Due to the promising results of this open-label pilot trial, a further, large-scale, randomized, placebo-controlled trial using this dosage is ongoing. 33 
Location of injections
Several studies of onabotulinumtoxinA have included a protocol of injections that avoid the trigone. The presumed reason for this is to avoid possible vesicoureteric reflux that may be caused by weakening of the trigone musculature. However, more recent descriptions have proposed also injecting the trigone, given the high number of sensory receptors in this area. Abdel-Meguid 34 objectively evaluated this in a randomized, placebo-controlled study of 36 patients with SCI that compared the effects of 300 U of intradetrusor onabotulinumtoxinA excluding the trigone (n=18) and The primary outcome measure of incontinence episodes at week 8 decreased by 52.4% in the non-trigone group versus 80.9% in the trigone group (number of patients needed to treat 1.91 versus 1.23, P,0.001); complete dryness was achieved in 33.3% versus 66.7% of patients (number needed to treat three versus 1.5, P,0.001); and quality of life score was decreased by 46.76% versus 48.13% (number needed to treat 2.14 versus 2.08, not significant). Further, there was a significant increase in reflex volumes in the trigone group (60% in the non-trigone group versus 82.5% in the trigone group, P,0.001). There was no significant difference with regard to improvement in maximum cystometric capacity (66.2% versus 68.4%, respectively), or drop in maximal detrusor pressure (−42.3% versus −41.9%). Importantly, no subjects in this study had worsening or new vesicoureteral reflux, which is the potential concern if not treating the trigone area. Based on the promising results of this small study, ie, an improved effect of onabotulinumtoxinA when the trigone is included, it seems important to further evaluate this concept in larger trials, to ensure that the lack of increased reflux was not a false-negative finding in the trigone-treated group due to small numbers of study participants.
Mascarenhas et al 35 reported a prospective study evaluating the effect of intratrigonal injections of onabotulinum-toxinA on the antireflux mechanism and their short-term efficacy. Twenty-one patients with incontinence due to NDO received detrusor injections of onabotulinumtoxinA 300 U, including 50 U into the trigone. At baseline, 20 patients had no vesicoureteral reflux and one had grade II unilateral vesicoureteral reflux. Postoperative evaluation revealed no cases of vesicoureteral reflux, and resolution in the one case with this problem at baseline. Hydronephrosis was present in five patients (23.8%) before injection but in only one patient (4.8%) at follow-up evaluation (P=0.066). Therefore, from the few small studies in this area, it seems safe at least to include the trigone in the treatment algorithm.
Another significant area to consider is whether to inject intramuscularly into the detrusor, or whether similar benefits can be achieved by just injecting the suburothelium. Presumably, if some of the major targets for benefit of botulinum toxin A in the bladder lie within the suburothelium (ie, sensory receptors P2X3 and transient receptor potential cation channel subfamily V member 1), 10,30 extensive benefits may be expected from injections in this area. Avoiding the detrusor muscle itself, and thus avoiding weakening it, might be beneficial in people with neurogenic overactive bladder who are still voiding to empty their bladder, so as to avoid retention. A small study of 32 people with SCI and severe neurogenic overactive bladder requiring intermittent catheterization underwent either intradetrusor or subepithelial injections of onabotulinumtoxinA, 36 and results in the two groups were comparable, with 64.3% of patients in the intradetrusor group and 88.8% of those in the suburothelial group being subjectively satisfied with the treatment. Both treatment groups experienced significant improvement with regard to decreasing frequency of catheterization, improved incontinence episodes, increased volumes per catheterization, and cystometric capacity. The only significant difference was that improvement of detrusor compliance was greater in the intradetrusor group. In a study investigating the efficacy and safety of suburothelial injections of different doses of onabotulinumtoxinA for the treatment of detrusor overactivity (n=40 for neurogenic and n=35 for idiopathic), doses of 100 U, 150 U, or 200 U were injected at 40 sites. 37 At 3 months, an "excellent" outcome was obtained in 34.8%, 36%, and 40.7% of patients treated with 100 U, 150 U, and 200 U of onabotulinumtoxinA, respectively. The duration of therapeutic effect was significantly shorter in the 100 U group than in the 150 U and 200 U groups. Despite the detrusor itself not being injected, there was still a high dose-dependent incidence of new-onset high post-void residual volume (.150 mL) in all three groups (30.4% in the 100 U group, 52% in the 150 U group, and 72% in the 200 U group). This study suggests that although suburothelial injections may be helpful by targeting afferent sensory receptors, there is still a relatively high incidence of urinary retention despite not injecting the detrusor muscle.
Long-term efficacy
In the studies reporting long-term efficacy to date, there seems to be no tachyphylaxis with repeated injections over time, and no loss of duration of effect with subsequent treatments, consistent with other uses of onabotulinumtoxinA.
Persistent effects of repeated injections were found in 17 subjects with NDO 38 who had a mean number of 5.4 (range three to nine) injections, for a total of 91 injections. No systemic side effects occurred in this group. The daily number of incontinence episodes decreased from 2.6 at baseline to zero after the first injection, and remained at zero after the last injection. Maximal cystometric capacity and reflex volume increased significantly, and maximal detrusor pressure decreased significantly after the first and last injection when compared with baseline.
A 6-year follow-up study 39 
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OnabotulinumtoxinA in SCi and MS this problem at baseline and resolution of the renal pelvis dilatation seen in nine subjects at baseline. There was a decrease in incontinence episodes (P,0.01), an increase in volume at first uninhibited detrusor contraction and in maximum bladder capacity (P,0.001), and a decrease in maximum pressure of uninhibited contractions (P,0.01). Eighty-eight percent of subjects were completely continent, the quality of life index increased significantly, and time between requested injections remained consistent.
Kennelly et al recently reported the results of their interim analysis of an open-label extension of the Phase III clinical trials. In this work, the long-term safety and efficacy of onabotulinumtoxinA was investigated in subjects with NDO, in whom the primary assessment was change from baseline in weekly urinary incontinence episodes at 6 weeks after each treatment. Subjects with MS or SCI underwent treatment with either 200 U or 300 U of onabotulinumtoxinA to the detrusor wall, with treatments repeated for up to five cycles. A total of 387, 336, 241, 113, and 46 patients received one, two, three, four, and five cycles of onabotulinumtoxinA, respectively, and their weekly number of incontinence episodes decreased markedly at 6 weeks (−22.7, −23.3, −23.1, −25.3, and −31.9 for the 200 U onabotulinumtoxinA group in cycles one to five). 40
Quality of life
Quality of life is consistently and markedly improved by use of onabotulinumtoxinA for neurogenic overactive bladder, with I-QOL scores being the main measure of quality of life in most studies. Schurch et al reported a study in which quality of life, as measured by I-QOL, was the primary outcome measure and was significantly improved in comparison with placebo for up to 6 months post-injection with doses of either 200 U or 300 U. 41 Health-related quality of life data have also been reported for the two main trials mentioned above. 42, 43 In these studies, health-related quality of life measures included the total I-QOL score 42 and three domain scores (avoidance and limiting behavior, psychosocial, and social embarrassment), the modified Overactive Bladder Patient Satisfaction with Treatment Questionnaire (OAB-PSTQ), and Patient Global Assessment. The primary time point was at post-treatment week 6. In the study reported by Chancellor et al, 43 improvements from baseline in I-QOL total score were greater (P,0.001) in both the 200 U and 300 U onabotulinumtoxinA groups versus placebo; also significantly improved in both treatment groups were the OAB-PSTQ (P,0.001) and the Patient Global Assessment (P#0.001). Sussman et al 42 looked at the same outcomes in the other Phase III study, and reported that the mean improve-ment in I-QOL total score at weeks 6 and 12 was significantly greater with onabotulinumtoxinA 200 U and 300 U versus placebo (∆12.3 for 200 U and ∆14.9 for 300 U versus placebo, P,0.001). The OAB-PSTQ results showed improvement in satisfaction in the onabotulinumtoxinA treatment groups (P,0.001), and greater proportions of onabotulinumtoxinAtreated patients reported being somewhat or very satisfied (77.5% for 200 U and 67.8% for 300 U versus 39.5% for placebo), and with significant progress toward or complete achievement of the primary treatment goal (62.9% for 200 U and 61.6% for 300 U versus 16.5% for placebo).
Side effects of intradetrusor onabotulinumtoxinA injections
The most common adverse event associated with this therapy is urinary tract infection, with an incidence in the large Phase III studies of 36% in the placebo group, 49% in the 200 U group, and 53% in the 300 U group. However, given that all groups had a high incidence of urinary tract infection, this may largely be due to either the disease process or the procedure of detrusor injection itself. The time course of the onset of urinary tract infection is not available, so any conclusions on the cause of this adverse event cannot be made. Increased urinary retention, as defined by post-void residual volume, was 3% in placebo group, 17% in the 200 U group, and 21% in the 300 U group. 25, 26 Dose-dependent increases in urinary retention are seen in other trials as well, as discussed above. Additionally, there was a need to start de novo catheterization in a significant number of subjects who were voiding at baseline, compared with placebo (44% of the 300 U dose, 31% of the 200 U dose group, and 7% of the placebo group). 25, 26 Of significant concern in these two studies is the increased incidence of muscular weakness, with 1.8% of the placebo group, 3.8% of the 200 U group, and 5.5% of the 300 U group developing increased weakness. It is unknown how many of the subjects suffering from new weakness had MS or SCI, with presumably some of the MS subjects having exacerbations, but regardless, the incidence was higher in the treatment groups. Two of the 28 subjects receiving onabotulinumtoxinA in the trial reported by Herschorn et al 24 also suffered from muscular weakness, both being people with SCI. The seemingly high incidence of new weakness in muscles distant from the injection site warrants further investigation.
Conclusion
Neurogenic overactive bladder continues to be a source of morbidity and mortality for people with MS and SCI, as well as significantly impacting quality of life. However, patients now have access to a treatment that can lead to dramatic improvements in many regards with onabotulinumtoxinA, for up to 9 months or more per treatment. At this point in time, this treatment is second-line to anticholinergic therapy, and will probably remain as such. However, onabotulinum-toxinA, when used in people who have failed or are intolerant of anticholinergic therapy, leads to consistent and dramatic reduction of incontinence, frequency, and damaging high detrusor pressures, as well as significant improvement in bladder volumes and quality of life. Importantly, for these patients with chronic long-term impairment, there is little or no loss of effect over time. As a result of the excellent outcomes of the studies to date, onabotulinumtoxinA into the detrusor is now gold standard therapy for patients with neurogenic overactive bladder who have failed on anticholinergic therapy or are intolerant to it.
